Valve designs for left ventricular conduits

Information

  • Patent Grant
  • 6641610
  • Patent Number
    6,641,610
  • Date Filed
    Wednesday, August 4, 1999
    25 years ago
  • Date Issued
    Tuesday, November 4, 2003
    21 years ago
Abstract
Disclosed is a conduit that provides a bypass around a stenosis or occlusion in a coronary artery. The conduit is adapted to be positioned in the myocardium to provide a passage for blood to flow from a heart chamber to a coronary artery, at a site distal to the blockage or stenosis in the coronary artery. The conduit has a one-way valve positioned therein to prevent the backflow of blood from the coronary artery into the heart chamber.
Description




FIELD OF THE INVENTION




This invention relates to apparatus and method for implanting a conduit to allow communication of fluids from one portion of a patient's body to another; and, more particularly, to a blood flow conduit to allow communication from a heart chamber to a vessel or vice versa, and/or vessel to vessel. Even more particularly, the invention relates to a left ventricular conduit and related conduit configurations for controlling the flow of blood through the conduit to achieve bypass of a stenosed or occluded coronary artery.




BACKGROUND OF THE INVENTION




Coronary artery disease is a major problem in the U.S. and throughout the world. Coronary arteries as well as other blood vessels frequently become clogged with plaque, which at the very least impairs the efficiency of the heart's pumping action, and can lead to heart attack, arrhythmias, and death. In some cases, these arteries can be unblocked through noninvasive techniques such as balloon angioplasty. In more difficult cases, a bypass of the blocked vessel is necessary.




In a bypass operation, one or more venous segments are inserted between the aorta and the coronary artery. The inserted venous segments or transplants act as a bypass of the blocked portion of the coronary artery and thus provide for a free or unobstructed flow of blood to the heart. More than 500,000 bypass procedures are performed in the U.S. every year.




Such coronary artery bypass surgery, however, is a very intrusive procedure that is expensive, time-consuming and traumatic to the patient. The operation requires an incision through the patient's sternum (sternotomy), and that the patient be placed on a bypass pump so that the heart can be operated on while not beating. A vein graft is harvested from the patient's leg, and a delicate surgical procedure is required to piece the bypass graft to the coronary artery (anastomosis). Hospital stays subsequent to the surgery and convalescence are prolonged. Furthermore, many patients are poor surgical candidates due to other concomitant illnesses.




As mentioned above, another conventional treatment is percutaneous transluminal coronary angioplasty (PTCA) or other types of angioplasty. However, such vascular treatments are not always indicated due to the type of location of the blockage or stenosis, or due to the risk of emboli.




Thus, there is a need for an improved bypass system that is less traumatic to the patient.




SUMMARY OF THE INVENTION




The preferred embodiments of the present invention address the need in the previous technology by providing a bypass system that avoids the sternotomy and other intrusive procedures normally associated with coronary bypass surgery. These embodiments also free the surgeon from the need to perform multiple anastomoses as is necessary in the current process.




The preferred device provides a conduit or shunt for diverting blood directly from the left ventricle of the heart to a coronary artery, at a point distal to the blockage or stenosis, thereby bypassing the blocked portion of the vessel. The conduit preferably comprises a tube adapted to be positioned in the myocardium and having a one way valve therein. The valve prevents the backflow of blood from the coronary artery into the left ventricle.




The conduit device is delivered through the coronary artery to a position distal the blockage or stenosis. At that position, the coronary artery, the myocardium and the wall of the left ventricle are pierced to provide an opening or channel completely through from the coronary artery to the left ventricle of the heart. The conduit is then positioned in the opening to provide a permanent passage for blood to flow between the left ventricle of the heart and the coronary artery, distal to the blockage or stenosis. The conduit is sized so that one open end is positioned within the coronary artery, while the other open end is positioned in the left ventricle. The hollow lumen of the conduit provides a passage for the flow of blood.




To prevent the backflow of blood from the coronary artery to the left ventricle of the heart, the conduit is provided with a one-way valve. The valve is preferably a windsock type valve, a flapper valve, a bi- or tricuspid valve, a ball valve, a valve formed from the myocardium itself, or a valve that opens and closes in response to the contraction and relaxation of the heart muscle, or in response to the electrical signals in the heart.











BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1A

is a schematic, cross-sectional view of a human heart, showing a conduit in the myocardium of the heart for forming a bypass between the left ventricle and a coronary artery;





FIG. 1B

is an enlarged view of the bypass conduit of

FIG. 1A

;





FIG. 2

is a cross-sectional view of a windsock valve incorporated into a heart conduit in accordance with a preferred arrangement;





FIG. 3

is a perspective view of a flapper valve incorporated into a heart conduit in accordance with a preferred arrangement;





FIG. 4

is a perspective view of a tricuspid valve incorporated into a heart conduit in accordance with the preferred arrangement;





FIGS. 5A-D

are cross-sectional views of a valve formed from the myocardium for use in conjunction with a heart conduit in accordance with a preferred arrangement;





FIGS. 6A-B

are cross-sectional views of a valve that is activated by the contractions of the heart muscle for use in conjunction with a heart conduit in accordance with a preferred arrangement;





FIG. 7

is a cross-sectional view of a valve that is activated by the electrical signals in the heart muscle for use in conjunction with a heart conduit in accordance with a preferred arrangement;





FIG. 8

is a cross-sectional view of a ball valve incorporated into a heart conduit in accordance with a preferred arrangement;





FIGS. 9A-9B

are cross-sectional views of a valve with spring mechanisms incorporated into a heart conduit;





FIGS. 9C-9D

are cross-sectional views of a valve with a balloon mechanism incorporated into a heart conduit;





FIGS. 9E-9F

are cross-sectional views of a valve with an internal motor incorporated into a heart conduit;





FIG. 10A

is a partial cross-sectional view of a ball and cage valve incorporated into a heart conduit;





FIG. 10B

is a cross-sectional view of a ball valve incorporated into a heart conduit having a narrower distal end;





FIG. 10C

is a cross-sectional view of a ball valve incorporated into a heart conduit having a smooth taper.











DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT




As is well known, the coronary artery branches off the aorta and is positioned along the external surface of the heart wall. Oxygenated blood that has returned from the lungs to the heart then flows from the heart to the aorta. Some blood in the aorta flows into the coronary arteries, and the remainder of blood in the aorta flows on to the remainder of the body. The coronary arteries are the primary blood supply to the heart muscle and are thus critical to life. In some individuals, atherosclerotic plaque, aggregated platelets, and/or thrombi build up within the coronary artery, blocking the free flow of blood and causing complications ranging from mild angina to heart attack and death. The presence of coronary vasospasm, also known as “variant angina” or “Prinzmetal's angina,” compounds this problem in many patients.




As used herein, the term “heart chamber” primarily refers to the interior, or lumenal, aspect of the left or right ventricle or the left or right atrium. The term “conduit,” “stent,” and “tube” herein refer to physical structures, preferably primarily artificial, that can be positioned between two or more chambers or vessels, to allow blood flow from one chamber or vessel to another. A “shunt” is any natural or artificial passage between natural channels, such as heart chambers or blood vessels. The conduit in the preferred arrangement can be made of a variety of materials, including various metals, such as nitinol, or plastics.




As used herein, the term “heart wall” comprises any one or more of the following portions or layers of the mammalian heart: the epicardium, myocardium, endocardium, pericardium, interatrial septum, and interventricular septum.




The principles of the present invention are not limited to left ventricular conduits, and include conduits for communicating bodily fluids from any space within a patient to another space within a patient, including any mammal. Furthermore, such fluid communication through the conduits is not limited to any particular direction of flow and can be antegrade or retrograde with respect to the normal flow of fluid. Moreover, the conduits may communicate between a bodily space and a vessel or from one vessel to another vessel (such as an artery to a vein or vice versa). Moreover, the conduits can reside in a single bodily space so as to communicate fluids from one portion of the space to another. For example, the conduits can be used to achieve a bypass within a single vessel, such as communicating blood from a proximal portion of an occluded coronary artery to a more distal portion of that same coronary artery.




In addition, the conduits and related methods can preferably traverse various intermediate destinations and are not limited to any particular flow sequence. For example, in one preferred embodiment of the present invention, the conduit communicates from the left ventricle, through the myocardium, into the pericardial space, and then into the coronary artery. However, other preferred embodiments are disclosed, including direct transmyocardial communication from a left ventricle, through the myocardium and into the coronary artery. Thus, as emphasized above, the term “transmyocardial” should not be narrowly construed in connection with the preferred fluid communication conduits, and other nonmyocardial and even noncardiac fluid communication are preferred as well. With respect to the walls of the heart (and more specifically the term “heart wall”), the preferred conduits and related methods are capable of fluid communication through all such walls including, without limitation, the pericardium, epicardium, myocardium, endocardium, septum, etc.




The bypass which is achieved with certain preferred embodiments and related methods is not limited to a complete bypass of bodily fluid flow, but can also include a partial bypass which advantageously supplements the normal bodily blood flow. Moreover, the obstructions that are bypassed may be of a partial or complete nature, and therefore the terminology “bypass” or “occlusion” should not be construed to be limited to a complete bypass or a complete occlusion but can include partial bypass and partial occlusion as described.




The preferred conduits and related methods disclosed herein can also provide complete passages or partial passages through bodily tissues. In this regard, the conduits can comprise stents, shunts, or the like, and therefore provide a passageway or opening for bodily fluid such as blood. Moreover, the conduits are not necessarily stented or lined with a device but can comprise mere tunnels or openings formed in the tissues of the patient.




The conduits of the present invention preferably comprise both integral or one-piece conduits as well as plural sections joined together to form a continuous conduit. The present conduits can be deployed in a variety of methods consistent with sound medical practice including vascular or surgical deliveries, including minimally invasive techniques. For example, various preferred embodiments of delivery rods and associated methods are disclosed. In one embodiment, the delivery rod is solid and trocar-like. It may be rigid or semi-rigid and capable of penetrating the tissues of the patient and thereby form the conduit, in whole or in part, for purposes of fluid communication. In other preferred embodiments, the delivery rods may be hollow so as to form the conduits themselves (e.g., the conduits are preferably self-implanting or self-inserting) or have a conduit mounted thereon (e.g., the delivery rod is preferably withdrawn leaving the conduit installed). Thus, the preferred conduit device and method for installation is preferably determined by appropriate patient indications in accordance with sound medical practices.




In order to restore the flow of oxygenated blood through the coronary artery, the preferred arrangement provides for the shunting of blood directly from the heart to a site in the coronary artery which is distal the blockage or stenosis.




Although the specification herein will describe the conduit primarily with reference to the left ventricle, the preferred arrangement can be used with any of the four heart chambers, and with any coronary artery, including the left main coronary artery, the right coronary artery, the left anterior descending artery, the left circumflex artery, the posterior descending artery, the obtuse marginal branch or a diagonal branch.




A tunnel or opening is formed through the wall of the coronary artery and the heart wall and into the left ventricle of the heart which lies beneath, or deep to, the coronary artery. A conduit is positioned in the opening to keep it open, and a one-way valve is positioned within the conduit to prevent blood from flowing back into the left ventricle of the heart from the coronary artery.




The conduit may be introduced into the heart wall in a variety of ways, including by a catheter threaded through the femoral artery into the aorta and thence into the left ventricle and, if necessary, the left atrium; or by a catheter threaded through the femoral vein into the inferior vena cava and thence into the right atrium and right ventricle. Alternatively, the conduit may be introduced through a surgical incision in chest wall (thoracotomy) or sternum (sternotomy).




Further details regarding conduits and conduit delivery systems are described in U.S. patent applications entitled DELIVERY METHODS FOR LEFT VENTRICULAR CONDUIT, U.S. application Ser. No. 09/368,868, now U.S. Pat. No. 6,261,304; DESIGNS FOR LEFT VENTRICULAR CONDUIT, U.S. application Ser. No. 09/369,048, now U.S. Pat. No. 6,290,728; LEFT VENTRICULAR CONDUIT WITH BLOOD VESSEL GRAFT, U.S. application Ser. No. 09/369,061, now U.S. Pat. No. 6,254,564; LEFT VENTRICULAR CONDUITS TO CORONARY ARTERIES AND METHODS FOR CORONARY BYPASS, U.S. application Ser. No. 09/369,039, now abandoned; and BLOOD FLOW CONDUIT DELIVERY SYSTEM AND METHOD OF USE, U.S. application Ser. No. 09/368,644, now U.S. Pat. No. 6,302,892, filed on the same day as the present application, and U.S. Pat. Nos. 5,429,144, and 5,662,124, the disclosures of which are all hereby incorporated by reference in their entirety.




The opening through the heart wall (including endocardium, myocardium, and epicardium) and coronary artery can be formed in a variety of ways, including by knife or scalpel, electrocautery, cryoablation, radiofrequency ablation, ultrasonic ablation, and the like. Other methods will be apparent to those of ordinary skill in the art.




Referring now to

FIGS. 1A and 1B

, a coronary artery bypass is accomplished by disposing a conduit


12


(

FIG. 1B

) in a heart wall or myocardium MYO of a patient's heart PH (FIG.


1


A). The conduit


12


preferably extends from the left ventricle LV of heart PH to a clogged coronary artery CA at a point downstream of a blockage BL to create a passageway therethrough. Conduit


12


is preferably made of a biocompatible material such as stainless steel or nitinol, although other materials such as Ti, Ti alloys, Ni alloys, Co alloys and biocompatible may also be used. In one embodiment, conduit


12


has a one way valve


14


to allow blood to flow from the left ventricle LV to the coronary artery CA. Although the conduit


12


may elastically deform under the contractive pressure of the heart muscle during systole, the stent remains open to allow blood to pass from the patient's left ventricle LV into the coronary artery CA. During diastole, the blood pumped into coronary artery through passageway is blocked by one-way valve


14


from returning to left ventricle LV.




One embodiment of the preferred arrangement is illustrated in FIG.


2


. The valve


10


incorporates a design similar to a windsock. The valve


10


is preferably formed from a biocompatible fabric-like material incorporated during the construction of the conduit


12


. The high-pressure blood flow causes the valve


10


to open, while the backflow of blood catches the edges of the valve


10


and causes it to close, stopping the flow. The valve


10


can be positioned anywhere along the length of the conduit


12


.




The valve


10


is preferably constructed from a biocompatible and very compliant fabric or other material that is pushed aside by the high forward blood pressure created from the contraction of the heart muscle, but opens to “catch” the back-flow of blood passing back through the conduit


12


. The valve


10


is preferably constructed by incorporating the fabric or other material into the conduit


12


directly during its manufacture. This allows the valve


10


and conduit


12


to be introduced as a single unit.




Another embodiment of the preferred arrangement is illustrated in FIG.


3


. This valve


15


is a type of “flapper valve” that is built onto the end of the conduit


12


that is positioned in the coronary artery. The high-pressureblood flow opens the flap


15


and the backflow of blood causes the flap


15


to shut. This flap


15


is slightly larger than the conduit


12


inner diameter (D) to accomplish this action and to ensure a proper seal. The valve


15


is preferably formed from the same material as the conduit


12


and the two are preferably introduced as a single unit. Alternatively, the valve


15


may be attached as a secondary operation once the conduit


12


is in place.




The third embodiment of the valve


16


is illustrated in FIG.


4


. This valve


16


is similar to a natural heart valve. A bi- or tricuspid arrangement of semi-circular spheres is forced open by the high-pressure flow and collapses back to prevent back-flow of blood through the conduit


12


. This valve


16


is preferably made from the same material as the conduit


12


, or alternatively, from a thin biocompatible material that is built onto the conduit


12


. Preferably, the valve


16


and the conduit


12


are manufactured together and introduced as a single unit. Alternatively, the valve


16


may be attached to the conduit


12


in a secondary operation once the conduit


12


is in place. The valve


16


may be placed at any location along the length of the conduit


12


.




A further embodiment of the conduit is illustrated in

FIGS. 5A-D

. Here, the heart wall, which includes the myocardium MYO, lying between the coronary artery CA and the left ventricle of the heart LV, is cut using known techniques to form a passage through the myocardium MYO.

FIG. 5A

shows the myocardium MYO after a cut or puncture has been made in it, with a free edge


17


shown at each margin of the cut or puncture.

FIG. 5B

shows the myocardium MYO after a jagged or irregular surface


19


has been made with a cutting tool in the free edge


17


of the myocardium MYO. Such cutting tools may include knives, scalpels, lasers, radiofrequency probes, and other cutting tools known to those of skill in the art.




As illustrated in

FIG. 5C

, two conduits, an upper or lower conduit, or a single conduit


18


having upper


18




a


and lower


18




b


components, is positioned in the passage. The myocardium MYO is left free between the two edges of the conduit


18


to form the valve


20


.

FIG. 5D

shows that during diastole, the edges or free portions of the myocardium MYO come together, closing the passage through the myocardium MYO. During systole, the free portions of the myocardium MYO can move away from one another as cardiac myofibrils contract, opening the passage through the myocardium MYO, as illustrated in FIG.


5


C. Thus, the heart muscle MYO itself can form at least part of the valve


20


in the conduit


18


to prevent the backflow of blood.




In another embodiment, the valve in the conduit may be controlled in response to the contractions of the heart. As illustrated in

FIGS. 6A and 6B

, two conduits (FIG.


6


A), an upper conduit


20


and lower conduit


22


, or a single conduit (

FIG. 6B

) having upper moveable components


20


and lower moveable components


22


, are positioned in the passage in the myocardium MYO between the left ventricle LV and the coronary artery CA. The conduit or conduits contain a valve


24


, which is normally in a closed position, and an actuator


26


, which is adapted to open the valve


24


in the conduit. During diastole, when the heart muscle MYO is relaxed, the two conduits or the two components of the conduit


20


,


22


are positioned such that the valve


24


remains closed. During systole, the two conduits or components


20


,


22


are brought close together, such that the actuator


26


forces the valve


24


to open and allows for the passage of blood therethrough. Thus, the contractions of the heart muscle MYO control the valve


24


in the conduit to prevent the backflow of blood during part of the cardiac cycle, for example diastole.




The valve


24


may also be controlled by a hydrodynamic or electric pump or motor, which is reponsive to the contractions of the heart, causing the valve


24


to open and close in response to various parts of the cardiac cycle.




A further embodiment of the preferred arrangement is illustrated in FIG.


7


. In this embodiment, electrical sensors


30


regulate the opening and closing of the valve


32


positioned within the conduit


34


. The sensor


30


senses the electrical signals produced in the heart muscle, and causes the valve


32


to open during systole, and to close during diastole. This is accomplished by having an actuator


36


act in response to the electrical signals detected by the sensor


30


, to open and close the valve


32


. For example, the valve


32


can be biased in a closed position. When the sensor


30


detects the electrical signal that occurs during or immediately precedes systole, e.g., a QRS complex in the electrocardiogram, the sensor


30


signals the actuator


36


to force open the valve


32


and allow for the flow of blood therethrough. During diastole, the sensor


30


signals the actuator


36


to allow the valve


32


to close and prevent any backflow of blood. Alternatively, the valve


32


can be biased in an open position. When the sensor


30


senses diastole, such as through coordination with the P wave or PR interval in the electrocardiogram, or, for example, after the sensor delays for a predetermined time period after the QRS complex occurs in the electrocardiogram, it signals the actuator


36


to close the valve


32


and prevent the backflow of blood.




Another embodiment is illustrated in FIG.


8


. This valve


42


is a type of “ball valve” that is built into the conduit


40


that is positioned in the coronary artery. The high-pressure blood flow from the left ventricle LV to the coronary artery CA opens the valve


42


by moving the ball


44


away from the opening


46


. The backflow of blood from the coronary artery CA to the left ventricle LV causes the ball


44


to seat against the opening


46


, thereby closing the valve


42


and preventing the backflow of blood. The valve


42


and the conduit


40


are preferably introduced as a single unit.




Another embodiment is illustrated in

FIGS. 9A and 9B

. The conduit


12


has a valve


48


with one or more spring mechanisms


50


within its walls. In diastole (FIG.


9


A), bloodflow pressure through the valve is relatively low, and the valve assumes a relatively closed position, impeding the passage of blood through the valve


48


. In systole (FIG.


9


B), flow pressure through the valve is relatively high, and the valve


48


opens as the spring mechanism


50


contracts, to allow blood to flow through the valve


48


.




Instead of a spring mechanism


50


, the walls of the conduit


12


can have other mechanisms therein to allow differential flow during various parts of the cardiac cycle. For example, the valve


48


can have a gas- or liquid-filled balloon


52


in its wall, as shown in

FIGS. 9C and 9D

. This balloon mechanism can contract (

FIG. 9D

, during systole) or expand (

FIG. 9C

, during diastole) in response to fluid pressure, to allow the valve


48


to open and close, respectively. Alternatively, the valve


48


can have an internal motor


54


, shown in

FIGS. 9E and 9F

, that opens and closes the valve


48


in response to electrical or mechanical signals from the heart during various parts of the cardiac cycle. For example, as illustrated in

FIG. 9E

, during diastole, the motor preferably closes the valve


48


, and during systole, the motor preferably opens the valve


48


.




Another embodiment of the valve mechanism is illustrated in FIG.


10


A. The conduit


12


has a ball valve


60


that is of the ball-and-cage variety, for example, like the Starr-Edwards heart valve known to those of skill in the art. This valve


60


typically has a wire or mesh cage


62


with a ball


64


within it. The conduit is positioned within the myocardium MYO. During blood flow from the left ventricle LV to the coronary artery CA, the ball


64


moves toward the apex of the cage


62


, permitting blood to flow around the ball


64


and through the conduit


12


. During backflow of blood from the coronary artery CA to the left ventricle LV, the ball


64


moves toward the base of the cage


62


and seats thereon, fitting tightly onto the base of the cage


62


, and blocking the flow of blood from the coronary artery CA to the left ventricle LV.





FIG. 10B

illustrates another embodiment wherein a ball


64


is provided within a conduit


12


that is wider at proximal end


56


facing the left ventricle, and narrower at distal end


58


facing the coronary artery.

FIG. 10C

illustrates a similar embodiment wherein the conduit


12


has a gradual taper from the proximal end


56


to distal end


58


. Like the embodiment of

FIG. 10A

, during blood flow from the proximal end


56


to distal end


58


, the ball


64


moves toward the coronary artery CA to allow blood flow around the ball through the conduit. In one embodiment, the cross-section of the conduit


12


in

FIGS. 10B and 10C

is noncircular, for example elliptical, to allow blood to flow around the ball


64


. During backflow from the coronary artery CA to the left ventricle LV, the ball moves against the base


59


of the conduit to block flow of blood therethrough.




The present vascular conduit and valve system provides significant improvements in the present treatment of blockages and significant stenoses in the coronary artery. Although the invention has been described in its preferred embodiments in connection with the particular figures, it is not intended that this description should be limited in any way.



Claims
  • 1. A device for treating a heart, the device comprising:at least one hollow implant defining a lumen, the at least one hollow implant being configured to be positioned in a heart wall between a heart chamber and a coronary vessel, wherein, when the at least one hollow implant is positioned in the heart wall, the lumen at least partially defines a blood flow passage between the heart chamber and the coronary vessel, and wherein the passage is at least partially closable in response to movement of cardiac tissue during diastole so as to at least partially obstruct blood flow therethrough.
  • 2. The device of claim 1, wherein the lumen is configured so that, when the at least one hollow implant is positioned in the heart wall, the lumen is open to permit blood flow through the passage during systole.
  • 3. The device of claim 1, wherein the at least one hollow implant includes a hollow tube.
  • 4. The device of claim 1, wherein the at least one hollow implant includes a conduit.
  • 5. The device of claim 1, wherein the at least one hollow implant includes a stent.
  • 6. The device of claim 1, wherein the at least one hollow implant includes two hollow implants.
  • 7. The device of claim 6, wherein the hollow implants are configured to be separated from each other when the hollow implants are positioned in the heart wall.
  • 8. The device of claim 6, wherein a length of each hollow implant is less than a thickness of the heart wall.
  • 9. The device of claim 1, wherein the at least one hollow implant is configured to be positioned in the heart wall between a left ventricle and a blood vessel.
  • 10. The device of claim 1, wherein the at least one hollow implant is configured to be positioned in the heart wall between the heart chamber and a coronary artery.
  • 11. The device of claim 1, wherein the at least one hollow implant is configured to be positioned in the heart wall between a left ventricle and a coronary artery.
  • 12. The device of claim 11, wherein the passage is configured to permit blood to flow from the left ventricle to the coronary artery when blood flow through the passage is not partially obstructed.
  • 13. The device of claim 1, wherein the passage is closable such that blood flow through the passage is fully obstructed in response to movement of the cardiac tissue during diastole.
  • 14. The device of claim 1, wherein the cardiac tissue includes the heart wall.
  • 15. A device for treating a heart, the device comprising:at least one hollow implant defining a lumen, the at least one implant being configured to be positioned in a heart wall between a heart chamber and a coronary vessel, wherein, when the at least one hollow implant is positioned in the heart wall, the lumen at least partially defines a blood flow passage between the heart chamber and the coronary vessel, and wherein the passage is at least partially closable by cardiac tissue entering the passage so as to at least partially obstruct blood flow therethrough during at least a portion of a cardiac cycle.
  • 16. The device of claim 15, wherein the lumen is configured so that, when the at least one hollow implant is positioned in the heart wall, the lumen is open to permit blood flow through the passage during systole.
  • 17. The device of claim 15, wherein the at least one hollow implant includes a hollow tube.
  • 18. The device of claim 15, wherein the at least one hollow implant includes a conduit.
  • 19. The device of claim 15, wherein the at least one hollow implant includes a stent.
  • 20. The device of claim 15, wherein the at least one hollow implant includes two hollow implants.
  • 21. The device of claim 20, wherein the hollow implants are configured to be separated from each other when the hollow implants are positioned in the heart wall.
  • 22. The device of claim 21, wherein a length of each hollow implant is less than a thickness of the heart wall.
  • 23. The device of claim 15, wherein the at least one hollow implant is configured to be positioned in the heart wall between a left ventricle and a blood vessel.
  • 24. The device of claim 15, wherein the at least one hollow implant is configured to be positioned in the heart wall between the heart chamber and a coronary artery.
  • 25. The device of claim 15, wherein the at least one hollow implant is configured to be positioned in the heart wall between a left ventricle and a coronary artery.
  • 26. The device of claim 25, wherein the passage is configured to permit blood to flow from the left ventricle to the coronary artery when blood flow through the passage is not partially obstructed.
  • 27. The device of claim 15, wherein, when the at least one hollow implant is positioned in the heart wall, the passage is closable by the cardiac tissue so as to fully obstruct the blood flow therethrough during at least a portion of the cardiac cycle.
  • 28. The device of claim 15, wherein the cardiac tissue includes the heart wall.
  • 29. The device of claim 28, wherein, when the at least one hollow implant is positioned in the heart wall, the passage is at least partially closable by portions of the heart wall coming together so as to at least partially obstruct blood flow therethrough during at least a portion of the cardiac cycle.
  • 30. The device of claim 15, wherein, when the at least one hollow implant is positioned in the heart wall, the passage is at least partially closable by the cardiac tissue so as to at least partially obstruct blood flow therethrough during diastole.
  • 31. The device of claim 1, wherein the cardiac tissue is myocardial tissue.
  • 32. The device of claim 15, wherein the cardiac tissue is myocardial tissue.
CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application Ser. No. 60/099,777, filed Sep. 10, 1998.

US Referenced Citations (214)
Number Name Date Kind
3671979 Moulopoulos Jun 1972 A
3858246 Milo Jan 1975 A
3911502 Boretos Oct 1975 A
3926215 Macleod Dec 1975 A
4441215 Kaster Apr 1984 A
4503568 Madras Mar 1985 A
4655773 Grassi Apr 1987 A
4680031 Alonso Jul 1987 A
4733665 Palmaz Mar 1988 A
4769029 Patel Sep 1988 A
4979955 Smith Dec 1990 A
4995857 Arnold Feb 1991 A
5035702 Taherei Jul 1991 A
5135467 Citron Aug 1992 A
5193546 Shaknovich Mar 1993 A
5258008 Wilk Nov 1993 A
5287861 Wilk Feb 1994 A
5330486 Wilk Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5344426 Lau et al. Sep 1994 A
5385541 Kirsch et al. Jan 1995 A
5397351 Pavcnik Mar 1995 A
5409019 Wilk Apr 1995 A
5423744 Gencheff et al. Jun 1995 A
5423851 Samuels Jun 1995 A
5429144 Wilk Jul 1995 A
5443497 Venbrux Aug 1995 A
5456712 Maginot Oct 1995 A
5456714 Owen Oct 1995 A
5470320 Tiefenbrun et al. Nov 1995 A
5487760 Villafana Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5527337 Stack et al. Jun 1996 A
5554185 Block et al. Sep 1996 A
5571215 Sterman et al. Nov 1996 A
5578075 Dayton Nov 1996 A
5593434 Williams Jan 1997 A
5609626 Quijano et al. Mar 1997 A
5618299 Khosravi et al. Apr 1997 A
5655548 Nelson et al. Aug 1997 A
5662124 Wilk Sep 1997 A
5713950 Cox Feb 1998 A
5755682 Knudson et al. May 1998 A
5758663 Wilk et al. Jun 1998 A
5797933 Snow et al. Aug 1998 A
5810836 Hussein et al. Sep 1998 A
5824038 Wall Oct 1998 A
5824071 Nelson et al. Oct 1998 A
5830222 Makower Nov 1998 A
5843163 Wall Dec 1998 A
5851232 Lois Dec 1998 A
5855597 Jayaraman Jan 1999 A
5865723 Love Feb 1999 A
5876419 Carpenter et al. Mar 1999 A
5878751 Hussein et al. Mar 1999 A
5908028 Wilk Jun 1999 A
5908029 Knudson et al. Jun 1999 A
5931868 Gross Aug 1999 A
5935119 Guy et al. Aug 1999 A
5935161 Robinson et al. Aug 1999 A
5935162 Dang Aug 1999 A
5944019 Knudson et al. Aug 1999 A
5961548 Shmulewitz Oct 1999 A
5968093 Kranz Oct 1999 A
5971993 Hussein et al. Oct 1999 A
5976159 Bolduc et al. Nov 1999 A
5976169 Imran Nov 1999 A
5976181 Whelan et al. Nov 1999 A
5976182 Cox Nov 1999 A
5976192 McIntyre et al. Nov 1999 A
5976650 Campbell et al. Nov 1999 A
5979455 Maginot Nov 1999 A
5980548 Evans et al. Nov 1999 A
5980551 Summers et al. Nov 1999 A
5980552 Pinchasik et al. Nov 1999 A
5980553 Gray et al. Nov 1999 A
5980566 Alt et al. Nov 1999 A
5980570 Simpson Nov 1999 A
5984955 Wisselink Nov 1999 A
5984956 Tweden et al. Nov 1999 A
5984963 Ryan et al. Nov 1999 A
5984965 Knapp et al. Nov 1999 A
5989207 Hughes Nov 1999 A
5989287 Yang et al. Nov 1999 A
5993481 Marcade et al. Nov 1999 A
5993482 Chuter Nov 1999 A
5997563 Kretiers Dec 1999 A
5997573 Quijano et al. Dec 1999 A
6001123 Lau Dec 1999 A
6004261 Sinofsky et al. Dec 1999 A
6004347 McNamara et al. Dec 1999 A
6004348 Banas et al. Dec 1999 A
6007575 Samuels Dec 1999 A
6007576 McClellan Dec 1999 A
6010530 Goicoechea Jan 2000 A
6017365 Van Oepen Jan 2000 A
6029672 Vanney et al. Feb 2000 A
6033582 Lee et al. Mar 2000 A
6045565 Ellis et al. Apr 2000 A
6053911 Ryan et al. Apr 2000 A
6053924 Hussein Apr 2000 A
6053942 Eno et al. Apr 2000 A
6067988 Mueller May 2000 A
6068638 Makower May 2000 A
6071292 Makower et al. Jun 2000 A
6076529 Vanney et al. Jun 2000 A
6080163 Hussein et al. Jun 2000 A
6093166 Knudson et al. Jul 2000 A
6095997 French et al. Aug 2000 A
6102941 Tweden et al. Aug 2000 A
6106538 Shiber Aug 2000 A
6110201 Quijano et al. Aug 2000 A
6113630 Vanney et al. Sep 2000 A
6113823 Eno Sep 2000 A
6117165 Becker Sep 2000 A
6123682 Knudson et al. Sep 2000 A
6126649 VanTassel et al. Oct 2000 A
6139541 Vanney et al. Oct 2000 A
6152141 Stevens et al. Nov 2000 A
6159225 Makower Dec 2000 A
6162245 Jayaraman Dec 2000 A
6182668 Tweden et al. Feb 2001 B1
6186972 Nelson et al. Feb 2001 B1
6187034 Frantzen Feb 2001 B1
6190353 Makower et al. Feb 2001 B1
6193726 Vanney Feb 2001 B1
D438618 Solem Mar 2001 S
6196230 Hall et al. Mar 2001 B1
6197050 Eno et al. Mar 2001 B1
6203556 Evans et al. Mar 2001 B1
6214041 Tweden et al. Apr 2001 B1
6223752 Vanney et al. May 2001 B1
6231587 Makower May 2001 B1
6237607 Vanney et al. May 2001 B1
6238406 Ellis et al. May 2001 B1
6245102 Jayaraman Jun 2001 B1
6250305 Tweden Jun 2001 B1
6253768 Wilk Jul 2001 B1
6254564 Wilk et al. Jul 2001 B1
6258119 Hussein et al. Jul 2001 B1
6261304 Hall et al. Jul 2001 B1
6283951 Flaherty et al. Sep 2001 B1
6283983 Makower et al. Sep 2001 B1
6287317 Makower et al. Sep 2001 B1
6290719 Garberoglio Sep 2001 B1
6290728 Phelps et al. Sep 2001 B1
6293955 Houser et al. Sep 2001 B1
6302875 Makower et al. Oct 2001 B1
6302892 Wilk Oct 2001 B1
6306125 Parker et al. Oct 2001 B1
6330884 Kim Dec 2001 B1
6350248 Knudson et al. Feb 2002 B1
6361519 Knudson et al. Mar 2002 B1
6363938 Saadat et al. Apr 2002 B2
6363939 Wilk Apr 2002 B1
6375615 Flaherty et al. Apr 2002 B1
6379319 Garibotto et al. Apr 2002 B1
6387119 Wolf et al. May 2002 B2
6406488 Tweden et al. Jun 2002 B1
6406491 Vanney Jun 2002 B1
6409697 Eno et al. Jun 2002 B2
6409751 Hall et al. Jun 2002 B1
6423089 Gingras et al. Jul 2002 B1
6432126 Gambale et al. Aug 2002 B1
6432127 Kim et al. Aug 2002 B1
6432132 Cottone et al. Aug 2002 B1
6447522 Gambale et al. Sep 2002 B2
6447539 Nelson et al. Sep 2002 B1
6454760 Vanney Sep 2002 B2
6454794 Knudson et al. Sep 2002 B1
6458323 Boekstegers Oct 2002 B1
20010004683 Gambale et al. Jun 2001 A1
20010004690 Gambale et al. Jun 2001 A1
20010004699 Gittings et al. Jun 2001 A1
20010008969 Evans et al. Jul 2001 A1
20010012948 Vanney Aug 2001 A1
20010014813 Saadat et al. Aug 2001 A1
20010016700 Eno et al. Aug 2001 A1
20010025643 Foley Oct 2001 A1
20010027287 Shmulewitz et al. Oct 2001 A1
20010034547 Hall et al. Oct 2001 A1
20010037117 Gambale et al. Nov 2001 A1
20010037149 Wilk Nov 2001 A1
20010039426 Makower et al. Nov 2001 A1
20010039445 Hall et al. Nov 2001 A1
20010041902 Lepulu et al. Nov 2001 A1
20010047165 Makower et al. Nov 2001 A1
20010053932 Phelps et al. Dec 2001 A1
20020002349 Flaherty et al. Jan 2002 A1
20020004662 Wilk Jan 2002 A1
20020004663 Gittings et al. Jan 2002 A1
20020007138 Wilk et al. Jan 2002 A1
20020029079 Kim et al. Mar 2002 A1
20020032476 Gambale et al. Mar 2002 A1
20020032478 Boeksteggers et al. Mar 2002 A1
20020033180 Solem Mar 2002 A1
20020045928 Boekstegers Apr 2002 A1
20020049486 Knudson et al. Apr 2002 A1
20020058897 Renati May 2002 A1
20020062146 Makower et al. May 2002 A1
20020065478 Knudson et al. May 2002 A1
20020072699 Knudson et al. Jun 2002 A1
20020077566 Laroya et al. Jun 2002 A1
20020092535 Wilk Jul 2002 A1
20020095111 Tweden et al. Jul 2002 A1
20020100484 Hall et al. Aug 2002 A1
20020111669 Pazienza et al. Aug 2002 A1
20020111672 Kim et al. Aug 2002 A1
20020116044 Cottone, Jr. et al. Aug 2002 A1
20020123698 Garibotto et al. Sep 2002 A1
20020144696 Sharkawy et al. Oct 2002 A1
20020161424 Rapacki et al. Oct 2002 A1
20020165479 Wilk Nov 2002 A1
20020165606 Wolf et al. Nov 2002 A1
Foreign Referenced Citations (101)
Number Date Country
0 732 088 Sep 1996 EP
0 824 903 Feb 1998 EP
0 876 803 Nov 1998 EP
0 903 123 Mar 1999 EP
0 904 745 Mar 1999 EP
0 955 017 Nov 1999 EP
0 955 019 Nov 1999 EP
0 962 194 Dec 1999 EP
1 020 166 Jul 2000 EP
1 027 870 Aug 2000 EP
1 097 676 May 2001 EP
1 166 721 Jan 2002 EP
2 316 322 Feb 1998 GB
9846119 Oct 1988 WO
WO 9416629 Aug 1994 WO
9713463 Apr 1997 WO
9713471 Apr 1997 WO
WO 9718768 May 1997 WO
9727893 Aug 1997 WO
9727897 Aug 1997 WO
9727898 Aug 1997 WO
9732551 Sep 1997 WO
WO 9741916 Nov 1997 WO
WO 9743961 Nov 1997 WO
WO 9802099 Jan 1998 WO
9806356 Feb 1998 WO
9808456 Mar 1998 WO
9810714 Mar 1998 WO
9816161 Apr 1998 WO
WO 9819607 May 1998 WO
WO 9825549 Jun 1998 WO
WO 9844869 Oct 1998 WO
9846115 Oct 1998 WO
WO 9849964 Nov 1998 WO
WO 9853759 Dec 1998 WO
WO 9855027 Dec 1998 WO
WO 9857591 Dec 1998 WO
9908624 Feb 1999 WO
9917683 Apr 1999 WO
9921490 May 1999 WO
WO 9921510 May 1999 WO
WO 9922655 May 1999 WO
9925273 May 1999 WO
WO 9932051 Jul 1999 WO
9936000 Jul 1999 WO
9936001 Jul 1999 WO
WO 9937218 Jul 1999 WO
9938459 Aug 1999 WO
9940868 Aug 1999 WO
WO 9947071 Sep 1999 WO
WO 9947078 Sep 1999 WO
WO 9948427 Sep 1999 WO
9948545 Sep 1999 WO
9949793 Oct 1999 WO
9949910 Oct 1999 WO
9951162 Oct 1999 WO
9953863 Oct 1999 WO
9960941 Dec 1999 WO
9962430 Dec 1999 WO
0009195 Feb 2000 WO
WO 0010623 Mar 2000 WO
0012029 Mar 2000 WO
0015146 Mar 2000 WO
0015147 Mar 2000 WO
0015148 Mar 2000 WO
0015149 Mar 2000 WO
0015275 Mar 2000 WO
WO 0018325 Apr 2000 WO
WO 0018326 Apr 2000 WO
0021436 Apr 2000 WO
0021461 Apr 2000 WO
0021463 Apr 2000 WO
WO 00183331 Apr 2000 WO
0024449 May 2000 WO
0033725 Jun 2000 WO
WO 0035376 Jun 2000 WO
WO 0036997 Jun 2000 WO
0041632 Jul 2000 WO
0041633 Jul 2000 WO
0045711 Aug 2000 WO
WO 0048530 Aug 2000 WO
0056387 Sep 2000 WO
WO 0056387 Sep 2000 WO
0066007 Nov 2000 WO
0066009 Nov 2000 WO
0066035 Nov 2000 WO
0071195 Nov 2000 WO
WO 0108602 Feb 2001 WO
0110340 Feb 2001 WO
0110341 Feb 2001 WO
0110347 Feb 2001 WO
0110348 Feb 2001 WO
0110349 Feb 2001 WO
WO 0110350 Feb 2001 WO
WO 0117440 Mar 2001 WO
WO 0126562 Apr 2001 WO
WO 0149187 Jul 2001 WO
WO 0154625 Aug 2001 WO
WO 0170133 Sep 2001 WO
WO 0202163 Jan 2002 WO
WO 0202168 Jan 2002 WO
Non-Patent Literature Citations (18)
Entry
US 6,331,185, 12/2001, Gambale et al. (withdrawn)
American Medical Association Publication; International Cardiovascular Society, “Myocardial Boring for the Ischemic Heart,” A. Wakabayashi, M.D., et al.; Fifteenth Scientific Meeting, Atlantic City, NJ, Jun. 16 and 17, 1967; Archives of Surgery, pp. 743-752, vol. 95, No. 5, Nov. 1967.
The Journal of Thoracic and Cardiovascular Surgery, “Experimental evaluation of myocardial tunnelization as a method of myocardial revascularization,” I. Anabtawi, M.D. et al., pp. 638-646, Nov. 1969.
American Heart Journal, “Effects of laser irradiation delivered by flexible fiberoptic system on the left ventricular internal myocardium,” G. Lee, M.D. et al., pp. 587-590, vol. 106, No. 3, Sep. 1983.
Texas Heart Institute Journal, “Transmyocardial Laser Revascularization,” D. A. Cooley, M.D. et al., pp. 220-224, vol. 21, No. 3, 1994.
American Journal of Physiology, “Transmural myocardial perfusion during restricted coronary inflow in the awake dog,” R. Bache et al., pp. H645-651, vol. 232, No. 6, Jun. 1977.
The Annals of Thoracic Surgery, “Myocardial Canalization,” A. H. Khazei, M.D. et al., vol. 6, No. 2, Aug. 1968.
Surgical Forum, “Proceedings of the 24th Annual Sessions of the Forum on Fundamental Surgical Problems, 54th Clinical Congress of the American College of Surgeons, Chicago, Illinois, Oct., 1968,” pp. 156-159, American College of Surgeons, Chicago, Illinois.
Tweden et al, “Ventriculocoronary Artery Bypass (VCAB), a Novel Approach to Myocardial Revascularization” 2/2000.
Gardner, M.D. et al., “An Experimental Anatomic Study of Indirect Myocardial Revascularization,” Journal of Surgical Research, May 1971, vol. 11, No. 5, pp. 243-247.
Palmaz et al., “Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog,” AJR, 1985, vol. 145, pp. 821-825.
Palmaz et al., “Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertension,” AJR, 1986, vol. 147, pp. 1251-1254.
Richter, M.D. et al., “Transjugular Intrahepatic Portacaval Stent Shunt: Preliminary Clinical Results,” Radiology, 1990, vol. 174, No. 3, pp. 1027-1030.
Zemel, M.D. et al., “Percutaneous Transjugular Portosystemic Shunt,” JAMA, vol. 266, No. 3, pp. 390-393.
Massimo, M.D. et al., “Myocardial Revascularization by a New Method of Carrying Blood Directly from the Left Ventricular Cavity into the Coronary Circulation,” Journal of Thoracic Sueons, Aug. 1997, vol. 34, No. 2, pp. 257-264.
Lary, M.D. et al., “Myocardial Revascularization Experiments Using the Epicardium,” Archives of Surgery, Jan. 1969, vol. 98, No. 1, pp. 69-72.
Munro, M.D. et al., “The possibility of myocardial revascularization by creation of a left ventriculocoronary artery fistula,” Journal of Thoracic and Cardiovascular Surgery, Jul. 1969, vol. 58, No. 1, pp. 25-32.
Kuzela, M.D. et al., “Experimental evaluation to direct transventricular revascularization,” The Journal of Thoracic and Cardiovascular Surgery, Jun. 1969, vol 57, No. 6, pp. 770-773.
Provisional Applications (1)
Number Date Country
60/099777 Sep 1998 US